(Total Views: 573)
Posted On: 01/18/2019 2:13:10 AM
Post# of 30067
One of the authors Heinrich Jasper, PhD has done extensive research on MANF.
He is a Buck professor and staff scientist at Genentech.
Amarantus and Dr. Jasper along with Deepak Lamba, PhD, and Postdoctoral Fellow Joanna Neves, PhD began working together in 2014.
https://www.sec.gov/Archives/edgar/data/14248...ex99-1.htm
Heimlich is now a staff scientist working at Genentech and is still working on MANF studies.
One of Idea Phrama's clients is Genentech
http://ideapharma.com/about
In 2017 there was an article
"Orphan drugs and why everyone wants one!" written by James Bohan
http://ideapharma.com/junkie/orphan-drugs-and...-wants-one
If anyone was unaware, besides the many patents in multiple countries,
MANF also was awarded
Orphan Drug Designations for
Retinitis Pigmentosa (RP). In both the US and EU
Retinal Artery Occlusion (RAO) US
Just some back story.
Aloha
He is a Buck professor and staff scientist at Genentech.
Amarantus and Dr. Jasper along with Deepak Lamba, PhD, and Postdoctoral Fellow Joanna Neves, PhD began working together in 2014.
https://www.sec.gov/Archives/edgar/data/14248...ex99-1.htm
Heimlich is now a staff scientist working at Genentech and is still working on MANF studies.
One of Idea Phrama's clients is Genentech
http://ideapharma.com/about
In 2017 there was an article
"Orphan drugs and why everyone wants one!" written by James Bohan
http://ideapharma.com/junkie/orphan-drugs-and...-wants-one
If anyone was unaware, besides the many patents in multiple countries,
MANF also was awarded
Orphan Drug Designations for
Retinitis Pigmentosa (RP). In both the US and EU
Retinal Artery Occlusion (RAO) US
Just some back story.
Aloha
(8)
(0)
